KR102302044B1 - 개질된 kz144 엔도리신 서열 - Google Patents

개질된 kz144 엔도리신 서열 Download PDF

Info

Publication number
KR102302044B1
KR102302044B1 KR1020167015821A KR20167015821A KR102302044B1 KR 102302044 B1 KR102302044 B1 KR 102302044B1 KR 1020167015821 A KR1020167015821 A KR 1020167015821A KR 20167015821 A KR20167015821 A KR 20167015821A KR 102302044 B1 KR102302044 B1 KR 102302044B1
Authority
KR
South Korea
Prior art keywords
lys
leu
ala
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167015821A
Other languages
English (en)
Korean (ko)
Other versions
KR20160085342A (ko
Inventor
슈테판 밀러
라인하드 슈테어너
하이케 슈튜어
Original Assignee
뤼산도 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뤼산도 아게 filed Critical 뤼산도 아게
Publication of KR20160085342A publication Critical patent/KR20160085342A/ko
Application granted granted Critical
Publication of KR102302044B1 publication Critical patent/KR102302044B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020167015821A 2013-11-14 2014-11-14 개질된 kz144 엔도리신 서열 Active KR102302044B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2013/073869 2013-11-14
PCT/EP2013/073869 WO2015070911A1 (en) 2013-11-14 2013-11-14 Modified kz144 endolysin sequence
PCT/EP2014/074671 WO2015071436A1 (en) 2013-11-14 2014-11-14 Modified kz144 endolysin sequence

Publications (2)

Publication Number Publication Date
KR20160085342A KR20160085342A (ko) 2016-07-15
KR102302044B1 true KR102302044B1 (ko) 2021-09-15

Family

ID=49582760

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015821A Active KR102302044B1 (ko) 2013-11-14 2014-11-14 개질된 kz144 엔도리신 서열

Country Status (10)

Country Link
US (1) US10184120B2 (enExample)
JP (1) JP6745720B2 (enExample)
KR (1) KR102302044B1 (enExample)
CN (1) CN105793419B (enExample)
AU (1) AU2014350104B2 (enExample)
BR (1) BR112016011091B1 (enExample)
CA (1) CA2929686C (enExample)
EA (1) EA035959B1 (enExample)
MX (1) MX374403B (enExample)
WO (2) WO2015070911A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151228A3 (en) 2015-09-17 2023-06-14 Contrafect Corporation Lysin polypeptides active against gram-negative bacteria
CN109072211B (zh) * 2016-04-28 2023-10-27 莱桑多股份公司 抗沙门氏菌的抗菌剂
EP3464583A1 (en) 2016-05-27 2019-04-10 Sasinapas Co., Ltd. Endolysin variant
WO2018100408A1 (en) * 2016-11-30 2018-06-07 Sasinapas Co.,Ltd. Modified peptides
US11208643B2 (en) * 2017-04-03 2021-12-28 Sasinapas Co., Ltd. Engineered gram-negative endolysins
EP3802620A1 (en) * 2018-05-30 2021-04-14 Lysando AG Novel antimicrobial fusion proteins
CN111304181B (zh) * 2020-02-17 2021-11-23 华东理工大学 一种基因工程改造后的副溶血性弧菌噬菌体裂解酶及其制备方法和应用
KR20250044545A (ko) 2023-09-23 2025-04-01 조배근 사료급이기 청소기

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149792A2 (en) 2009-06-26 2010-12-29 Katholieke Universiteit Leuven, K.U. Leuven R&D Antimicrobial agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289092C (en) * 1987-01-15 1991-09-17 Robert A. Hallewell Thermostable human cu/zn superoxide dismutase muteins
EP0285123A3 (en) 1987-04-03 1989-02-01 Stabra AG A method for complete mutagenesis of nucleic acids
ZA936811B (en) * 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
JPH08127540A (ja) * 1994-09-09 1996-05-21 Takeda Chem Ind Ltd 抗潰瘍医薬
JP2010536354A (ja) * 2007-08-22 2010-12-02 ヒグロス インベスト ゲーエムベーハー ヒトおよび動物のブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症において使用するための新しいタンパク質
GB0815484D0 (en) * 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
BRPI1015203B1 (pt) 2009-06-26 2021-06-01 Lysando Ag Proteína de fusão composta por uma endolisina e uma extensão de peptídeo anfifática, usos da mesma e composição farmacêutica que compreende a dita proteína
EP2470648B1 (en) * 2009-08-24 2019-04-10 Katholieke Universiteit Leuven K.U. Leuven R&D New endolysin obpgplys
MX340520B (es) * 2010-04-27 2016-07-12 Lysando Ag * Metodo de reduccion de biopeliculas.
GB201018518D0 (en) * 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
KR20130142837A (ko) * 2012-06-20 2013-12-30 한국외국어대학교 연구산학협력단 슈도모나스 에루기노사의 박테리오파아지 및 그 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010149792A2 (en) 2009-06-26 2010-12-29 Katholieke Universiteit Leuven, K.U. Leuven R&D Antimicrobial agents
JP2012530509A (ja) 2009-06-26 2012-12-06 カトリック ユニバーシテイト ルーベン ケイ．ユー． ルーベン アール アンド ディー 抗微生物剤

Also Published As

Publication number Publication date
JP2016537979A (ja) 2016-12-08
AU2014350104B2 (en) 2020-03-05
EA035959B1 (ru) 2020-09-07
MX2016006277A (es) 2017-01-05
CN105793419A (zh) 2016-07-20
CA2929686C (en) 2023-08-08
NZ719338A (en) 2022-03-25
WO2015070911A1 (en) 2015-05-21
EA201691004A1 (ru) 2017-01-30
JP6745720B2 (ja) 2020-08-26
US10184120B2 (en) 2019-01-22
WO2015071436A1 (en) 2015-05-21
BR112016011091A2 (pt) 2017-12-05
CA2929686A1 (en) 2015-05-21
US20160281074A1 (en) 2016-09-29
CN105793419B (zh) 2021-06-01
AU2014350104A1 (en) 2016-05-12
KR20160085342A (ko) 2016-07-15
BR112016011091B1 (pt) 2024-02-06
MX374403B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
KR102302044B1 (ko) 개질된 kz144 엔도리신 서열
AU2021282524B2 (en) New Antimicrobial Agents Against Staphylococcus Aureus
US10167462B2 (en) Modified EL188 endolysin sequence
KR102560651B1 (ko) 엔테로코커스 박테리아에 대한 신규한 항미생물제
AU2017255962B2 (en) Antimicrobial agents against Salmonella bacteria
EP3068877B1 (en) Modified kz144 endolysin sequence
EP3068878B1 (en) Modified el188 endolysin sequence
HK1228944A1 (en) Modified kz144 endolysin sequence
HK1228944B (en) Modified kz144 endolysin sequence
NZ719338B2 (en) Modified kz144 endolysin sequence
HK40014646B (en) New antimicrobial agents against staphylococcus aureus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P18-X000 Priority claim added or amended

St.27 status event code: A-2-2-P10-P18-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5